Evidence map›Paper›PMID 39159716›Full record

ArticleEuropean journal of pharmacology2024

CB-839 induces reversible dormancy in lung tumor-cells.

Azemat Jamshidi-Parsian, Samir V Jenkins, Amy Tran, Anna Bragg, Rylie Davis, Connor Griffin, Eric Siegel, Ruud P M Dings, Robert J Griffin, Gunnar Boysen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Advances in experimental medicine and biology · 2026
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Azemat Jamshidi-ParsianDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Samir V JenkinsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Amy TranDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Anna BraggDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Rylie DavisDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Connor GriffinDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Eric SiegelThe Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Ruud P M DingsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Robert J GriffinDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Gunnar BoysenDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. Electronic address: gboysen@uams.edu.

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

Glutaminase inhibitors are currently being explored as potential treatments for cancer. This study aimed to elucidate the molecular mechanisms underlying the effects of CB-839 on lung tumor cell lines compared to non-tumor cell lines. Viability assays based on NADPH-dependent dehydrogenases activity, ATP energy production, or mitochondrial reductase activity were used to determine that CB-839 caused significant tumor cell specific inhibition of cellular functions. Clonogenic survival assay revealed a dose dependent reduction in clonogenic survival of various lung tumor cells presenting estimated IC

Indexed as

ApoptosisBenzeneacetamidesGlutaminaseLung NeoplasmsAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalGlutamineHumansThiadiazolesAntineoplastic AgentsBenzeneacetamidesCB-839GlutaminaseGlutamineThiadiazolesCB-839GLS1 inhibitorGlutaminaseLung cancer

Identifiers

PMID39159716
PMCPMC12702564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.